Cost-effectiveness of prophylactic ramosetron in the prevention of postoperative nausea and vomiting
The results demonstrated that prophylactic use of ramosetron compared to no antiemetic therapy is highly cost-effective to prevent PONV for patients undergoing surgery from both healthcare payer and societal perspectives. The cost effectiveness is the result of the decrease in the incidence of PONV and the direct treatment costs of severe PONV with improved patient quality of life.
Authors
- D.H. Kim (ORCID: https://orcid.org/0000-0001-7780-0813)
- Yu-Seon Jung (ORCID: https://orcid.org/0000-0001-5807-5257)
- Sun-Young Jung
- Seung-Mi Lee
- Chul-Min Kim (ORCID: https://orcid.org/0000-0001-9974-3709)
Institutions
- University of Michigan (US)
- Daegu Catholic University (KR)
- Chung-Ang University (KR)
- Catholic University of Korea (KR)
Publication Details
- Journal
- PLoS ONE
- Published
- 2024-10-17
- DOI
- https://doi.org/10.1371/journal.pone.0309592
- Primary Topic
- Nausea and vomiting management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Research Foundation
- Ministry of Education
- Daiichi-Sankyo
- National Research Foundation of Korea